Clinical Trial

A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants

Name: A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants — clinical trial record (NCT07668154)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a multicenter, open-label, Phase II clinical study to assess the efficacy, safety, tolerability, PK characteristics, and immunogenicity of SKB571 in participants with recurrent or metastatic HNSCC.

Trial Details

NCT Number	NCT07668154
Lead Sponsor	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Conditions	HNSCC
Enrollment	30 participants
Start Date	2026-07-31
Primary Completion	2028-09-30 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-25